Open AccessPlatelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention
Author(s) -
Matthew J. Price,
Dominick J. Angiolillo,
Paul S. Teirstein,
Elizabeth O. Lillie,
Steven V. Manoukian,
Peter B. Berger,
JeanFrançois Tanguay,
Christopher P. Can,
Eric J. Topol
Publication year - 2011
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.111.029165
Subject(s) - medicine , percutaneous coronary intervention , cardiology , platelet , percutaneous , myocardial infarction
In the Gauging Responsiveness With A VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial, 6 months of high-dose clopidogrel did not reduce cardiovascular events compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity (OTR) after percutaneous coronary intervention, defined as OTR ≥230 P2Y12 reaction units according to the VerifyNow P2Y12 platelet function test. The aim of this analysis was to examine the relationship between outcomes and OTR over the course of the trial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom